Fluidigm (FLDM +54.0%), fresh off of a volatility halt, is up on more than triple normal volume clearing a five-week base in apparent response to an article in The Guardian about a DARPA-funded COVID-19 assay that can potentially identify carriers before they become infectious.
The blood test could possibly detect the presence
of the SARS-CoV-2 virus as early as 24 hour after infection, about four
days earlier than current assays, by “looking at the body’s immune
response to the virus” (implying an earlier type of antibody than IgM).
If the FDA signs off on emergency use, the test could be rolled out in
about a month.
DARPA is collaborating with medical schools at Mount Sinai, Duke and Princeton and Fluidigm on the project.
https://seekingalpha.com/news/3567791-fluidigm-up-54-on-potential-early-blood-test-for-coronavirus
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.